Celltrion reported on Tuesday that its treatments for autoimmune diseases and cancer continue to maintain a strong market position in Europe with consistent prescription rates.
The company’s performance is bolstered by stable prescriptions of its core products, alongside early successes from newly launched high-revenue items. This combination of established and new product adoption is fueling optimistic projections for the company’s financial outlook.
Data from IQVIA, a leading pharmaceutical market research firm, reveals that Celltrion’s flagship autoimmune disease treatment, the Remsima product line (IV·SC), commanded an impressive 68% combined market share in Europe as of Q3 2025, solidifying its dominance in prescriptions.
The growth of Remsima SC, the world’s only subcutaneous infliximab treatment, is particularly noteworthy. It achieved a 26% market share in Europe, marking a 2 percentage point increase from the previous quarter.
Celltrion’s other autoimmune disease treatment, Yuflyma (adalimumab), also maintained its leading position in European prescriptions with a 24% market share during the same period.
In oncology, Celltrion continues to make significant strides. Vegzelma (bevacizumab), a treatment for metastatic colorectal and breast cancers, secured the top spot in European prescriptions with a 26% market share.
While established products continue to perform well, Celltrion’s recently launched high-revenue offerings are also showing promising early results, raising expectations for rapid market penetration.
Omlyclo (omalizumab), a treatment for chronic spontaneous urticaria launched in Europe last September, has already captured about 70% of the local omalizumab market after winning multiple hospital group bids in the Netherlands.
Eydenzelt (ranibizumab), an ophthalmic treatment launched in December, quickly secured contracts with the National Health Service (NHS) in England, Scotland, and Northern Ireland, establishing a strong early foothold in key European markets.
Avtozma (tocilizumab), an autoimmune disease treatment, has captured approximately 80% of the private market in France by winning the majority of bids from private hospital groups.
A Celltrion spokesperson stated that its unique competitive advantages have enabled the flagship products, including the Remsima line, to achieve stable sales. It is committed to expanding the success of both the established and new products across Europe, aiming to drive a significant turnaround in its financial performance.